Ilika Q&A: 70-fold increase in production capability at new manufacturing facility (LON:IKA)

Ilika plc

Ilika plc (LON:IKA) Chief Executive Officer Graeme Purdy caught up with DirectorsTalk to discuss the progress of the new Stereax manufacturing facility, why a cleanroom is need, dealing with supply chain delays, more information on the key Tool 1 and Tool 2 equipment and maintaining a dialogue with Stereax customers.

Q1: Graeme, today you’ve provided an update to the market on the progress regarding the implementation of Ilika’s Stereax manufacturing facility. You mentioned that you’ve secured the lease on a 1,600m2 premises, how does this compare to the size of the facility housing your current Stereax pilot line?

A1: Yes, it’s quite a step up for us actually. I think the current pilot line has got a facility footprint of about 200m2 so the premises are about 8 times the size of where we currently operate. That actually gives us a much bigger set up in production capacity, the new facility will allow us to actually get a 70-fold increase in production capability by the time that’s it’s up and running.

Q2: You also mentioned the use of a cleanroom at the facility, why is that needed?

A2: Well, not all of the facility is in fact specified as a cleanroom but for some of the unit operations in the process of preparing the cells, we need to control both the humidity and the number of particles that are in the air in the rooms where we handle the wafers. In particular, we use photolithography and that process is sensitive to any dust or smaller particles that might interfere with the accuracy of the etching and therefore, we do have a cleanroom specification that we apply to make sure that the yield of the batteries is as high as possible.

Q3: You reported that your contractors are experiencing some supply chain delays for construction materials, could you just give us some examples of these and just explain how you’re managing the impact?

A3: The materials are often quite mundane things, if you imagine when you build a cleanroom, you need to put in place a whole of walls which are prefabricated panels and then quite a lot of piping associated with the specialty gases that we use in order to operate the processes. Also, there is quite a bit of ducting associated with handling the air so we extract air from the cleanroom and then we replace that with filtered air. So, actually it’s the supply of things like wall panels and ducting and stainless steel piping that is being affected, a lot of those materials are actually supplied from continental Europe.

So, we’re working together with the cleanroom contractor to make sure we set the right priorities in terms of which parts of the cleanroom should be brought on line first and making sure that we optimise the readiness of the cleanroom to start production as quickly as possible.

Q4: Are the ‘Tools’ that you mentioned, Tool 1 and Tool 2, the key items of equipment needed to make Stereax batteries?

A4: Yes, they are in fact the most expensive and also the most complex items of equipment, they’ve been on order since last year and the fabricators are making excellent progress. Both of them are very much on schedule, Tool 1 is coming from the US and Tool 2 is coming from Switzerland, and these are the bits of equipment that you actually use to deposit the active layers in the battery.

In addition, we’ve got some other equipment, particularly around the photolithography and capsulation and that’s also on order. One of those pieces of photolith equipment is already ready for dispatch to our new facility as soon as the facility is up and running and ready to accept it.

Q5: Whilst Ilika’s manufacturing facility is being completed, are you able to continue to engage with Stereax customers and to firm up commercial demand for your facility offtake?

A5: We continue to operate our pilot line so that’s continuing to make wafers of cells that we are shipping to customers and so we’re able to provide them with batteries for their prototyping activities.

Also, we’re maintaining a regular dialogue with those Stereax customers to make sure that they understand the timelines and we understand the likely volumes of offtake associated with this their applications. There’s a continuous dialogue that’s ongoing throughout this programme.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Ilika builds the manufacturing path for Goliath solid-state batteries

Ilika is building the manufacturing and licensing pathway needed to move its Goliath solid-state battery technology towards larger-scale commercial production.

Ilika: Stereax revenue growth and Goliath opportunities ahead

Morphose Capital Partners’ Dr Tom McColm discusses Ilika’s FY26 results, the outlook for Stereax commercial revenues, progress with Goliath and potential opportunities in automotive, defence and e-bikes.

Ilika CEO highlights Stereax revenue growth and Goliath defence interest

Ilika CEO Graeme Purdy discusses Stereax product revenue, planned M300 battery deliveries, Goliath 10Ah development, EV market trends and rising demand from the defence sector.

Ilika plc reaches a commercial turning point as new markets emerge for Stereax and Goliath (video)

Dr Tom McColm of Morphose Capital Partners explains why the company may be approaching an important commercial inflection point.

Ilika plc: Stereax Revenue Arrives as Goliath Draws Defence Interest (video)

Ilika plc CEO Graeme Purdy outlines how Stereax has started generating product-related revenue, why M300 battery deliveries remain on track and how Goliath’s 10Ah prototype is opening new opportunities in defence and sovereign battery supply.

Ilika builds commercial momentum across Stereax and Goliath batteries

Ilika Plc reports annual results for the year ended 30 April 2026, highlighting progress on its Stereax medical battery line and Goliath large-format batteries for EV, defence and consumer applications. The company began Stereax production and deliveries, shipped larger Goliath prototypes, secured further grant funding and raised £5 million post-period to accelerate commercialisation.

Search